INTRODUCTION
The development and utilization of Biotechnology-derived therapeutic products namely, recombinant DNA derived products emerges as the fastestgrowing segment in the pharmaceutical market. These products are large molecular weight and structurally complex molecules that are produced in living cells through genetic engineering. Biotechnology-derived therapeutic products are being developed over the past three decades and are under patent protection. The high cost of these therapeutic products has become a key issue in the battle concerning ever-increasing healthcare costs. The expiry of patent protection for biotechnology-derived therapeutic products of innovator origin has led to the development of Similar Biologics in India. Maintaining rapid as well as environmentally sustainable growth remains an important and achievable goal for India. In this concern, to meet unmet need and to append Make in India concept, pharmaceutical industry developed alternative similar biologics.
A Similar Biologic product is that which is similar in terms of quality, safety and efficacy to an approved Reference Biological product based on comparability. Similar Biologics also known as biosimilars, similar biological medicinal products, subsequent entry biological, second entry biological, biocomparable, biogenerics, multisource products, and off-patent biotech products as synonyms. Ÿ Approach to the quality comparability study Ÿ A specific section on the Quality Comparability Study has been added that explicitly defines a class of quality attributes -Critical Quality Attributes (CQAs) -where the proposed Similar Biologic has to be within the range that is established based on the Reference Biologic. This establishes a framework for product similarity that can be applied across all approved Similar Biologics and is consistent with the approach that the EMA and USFDA have taken.
Ÿ In addition to CQAs, the revised guidelines also define Key Quality Attributes(KQAs) which define a l l o t h e r p a r a m e te r s t h a t n e e d to b e wellcontrolled to ensure the safety and consistency of the product.
Ÿ This approach to the classification of quality attributes, establishes a solid foundation on which the remainder of the development program for a Similar Biologic can be built. In the future, it will facilitate the development of productspecific guidelines that will help establish the expectations for high quality Similar Biologics.
Ÿ Pre-approval clinical evaluation with respect to safety and efficacy Ÿ Revised guidelines require robust design of a comparative safety and efficacy study with the explicit requirement of not less than hundred evaluable patients on the test arm as per Indian GCP guidelines;
Ÿ This sets a minimum bar on the pre-approval data that needs to be gathered in a controlled clinical setting.
Ÿ Combined with the increased emphasis on product similarity and the existing requirements for pre-clinical and PK/PD studies this establishes a minimum bar for all future Similar Biologic approvals in the Country Ÿ Post-marketing safety evaluation using Phase IV studies Ÿ In addition, there has also been a significant addition to the post approval expectation of Phase IV safety study in more than two hundred evaluable patients, to create a minimum safety database of at least three hundred patients treated in a controlled setting for each approved Similar Biologic.
to the regulatory agency and is consistent with the expectations of key global regulatory agencies. Ÿ Post availability of toxicity study report, Clinical Trial Application to DCG(I) and toxicity study report to RCGM can be filed in parallel. However, DCG(I) will issue Clinical Trial NOC only upon clearance from RCGM.
Ÿ D a t a r e q u i r e m e n t s f o r C l i n i c a l Tr i a l Application:
Ÿ 2012 Guidance: No guidance on minimum Phase III sample size provided Ÿ Revised Guidelines: A clear expectation of a comparative safety and efficacy study with the explicit requirement of a not less than hundred evaluable subjects on the test arm; this sets a minimum bar on the pre-approval data to establish comparable efficacy.
Ÿ A protocol for a post marketing Phase IV open label, single arm safety study in not less than twohundred subjects on the Similar Biologic.
Ÿ This additional safety data will result in a robust safety database (100+200=300) that will help establish the safety of the proposed Similar Biologic.
Ÿ D a t a r e q u i r e m e n t s f o r M a r k e t i n g Authorization Application:
These guidelines not only addresses the regulatory pathway regarding manufacturing process and safety, efficacy and quality aspects for Similar Biologics, but also addresses the pre-market regulator y requirements including comparability exercise for quality, preclinical and clinical studies and post market regulatory requirements for Similar Biologics.
The changes made in the current guideline are intended to establish a robust platform that will facilitate the development of high quality products and create increased alignment between the Similar Biologics regulations in India and in global development.The revisions made are intended to deliver a clear and precise development pathway for the approval of Similar Biologics product, which in turn will have a significant impact on the healthcare related to these products in India. (RCGM) is responsible for overseeing the developmental and preclinical evaluation of Biotechnology-derived therapeutic products. The "Guidelines on Similar Biologics" prepared by both CDSCO and DBT to lay down the regulatory pathway for a Similar Biologic c l a i m i n g t o b e s i m i l a r t o a n a l r e a d y approvedinnovator product in the year 2012.During the preparation of Guidelines, it wasanticipated that there would need for ongoing review and revision from time to time.
The existing guidelines was revisedand implemented in the year 2016 which is made publicly available in CDSCO website. The revised guideline was prepared in consultation with Stakeholders and based on the real experiences to address the challenges faced during the previous years.
More detailed guidance and specific revisions are made in three distinct areas that are fundamental to the regulation of this class of complex products: 1) Approach to the quality comparability study.
2) Pre-approval clinical evaluation with respect to safety and efficacy 3) Post-marketing safety evaluation using Phase IV studies A specific section on the Quality Comparability Study has been added that explicitly defines a class of quality attributes -Critical Quality Attributes (CQAs) -where the Similar Biologic has to be within the range that is established based on the Reference Biologic. This establishes a framework for product similarity that can be applied across all approved Similar Biologics and is consistent with the approach that the EMA and USFDA have taken. In addition to CQAs, the revised guidelines also define Key Quality Attributes(KQAs) which define all other parameters that need to be well-controlled to ensure the safety and consistency of the product.
This approach to the classification of quality attributes, establishes a solid foundation on which the remainder of the development program for a Similar Biologic can be built. In the future, it will facilitate the development of product-specific guidelines that will help establish the expectations for high quality Similar Biologics.
Proposed guidelines require robust design of a comparative safety and efficacy study with the explicit requirement of not less than hundred evaluable patients on the test arm as per Indian Good Clinical Practice (GCP) guidelines. This sets a minimum bar on the pre-approval data that needs to be gathered in a controlled clinical setting. Combined with the increased emphasis on product similarity and the existing requirements for preclinical and PK/PD studies this establishes a minimum bar for all future Similar Biologic approvals in the Country. There has also been a significant addition to the post approval expectation of Phase IV safety study in more than two hundred evaluablepatients, to create a minimum safety database of at least three hundred patients treated in a controlled setting for each approved Similar Biologic.
This represents a significant enhancement to the scope of the safety database that will be available to the regulatory agency and is consistent with the expectations of key global regulatory agencies.
These guidelines are for the guidance of all stakeholders and are not meant to substitute or rephrase the Rules made under Drugs and Cosmetics Act, 1940 and Rules, 1945 or any other relevant Acts in this concern.
Ÿ Trained manpower availability in India Ÿ Some of the state FDA (Gujarat, Maharashtra) has also started online submissions.
Ÿ For export of unapproved r-DNA drugs and vaccines, firms seeking NOC to export the samples can now expect to get the NOC from CDSCO within 10 days of submission of requisite documents including a valid export order.
Ÿ RCGM Ÿ For r-DNA derived drugs like insulin, monoclonal antibody, etc., application can now be filed in parallel to Review Committee on Genetic Manipulation (RCGM) and the CDSCO office for seeking approval to conduct CT. Both the agencies can independently start their review process and issue their respective approvals to the firm.
Ÿ Condition for taking RCGM permission to import recombinant cell lines for research and development or commercial purpose has been discontinued.
